Yat Sun Or

2017

In 2017, Yat Sun Or earned a total compensation of $1.8M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 31% increase compared to previous year.

Compensation breakdown

Bonus$121,255
Non-Equity Incentive Plan$48,700
Option Awards$599,585
Salary$400,975
Stock Awards$574,369
Other$18,551
Total$1,763,435

Or received $599.6K in option awards, accounting for 34% of the total pay in 2017.

Or also received $121.3K in bonus, $48.7K in non-equity incentive plan, $401K in salary, $574.4K in stock awards and $18.6K in other compensation.

Rankings

In 2017, Yat Sun Or's compensation ranked 6,129th out of 14,666 executives tracked by ExecPay. In other words, Or earned more than 58.2% of executives.

ClassificationRankingPercentile
All
6,129
out of 14,666
58th
Division
Manufacturing
2,251
out of 5,770
61st
Major group
Chemicals And Allied Products
711
out of 2,074
66th
Industry group
Drugs
548
out of 1,730
68th
Industry
Pharmaceutical Preparations
430
out of 1,329
68th
Source: SEC filing on January 19, 2018.

Or's colleagues

We found four more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2017.

2017

Jay Luly

Enanta Pharmaceuticals

Chief Executive Officer

2017

Nathalie Adda

Enanta Pharmaceuticals

Chief Medical Officer

2017

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

2017

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

News

You may also like